Cancer Cell Evolution
We make genetic and functional maps of cancer cell evolution in patients by analysing multiple tumour samples from the same patient. In particular, we focus on childhood cancer where we try to unravel the genetic mechanisms leading to relapse and treatment resistance.
To achieve our aim, we use methods from species evolution (phylogenetics) to reconstruct the evolutionary history of individual tumours, from its founder cell up to clinical presentation, over treatment periods and at relapse. These data are used as the basis to understand how clinical biomarkers change over space and time in patients.
Also, we compare patterns of evolution to parameters of the tumour microenvironment in order to find out how surrounding factors shape the cancer genome through selection. In particular, we study the influence of chemotherapy effect and the patient’s immune response.
Examples of Recent Publications
Four evolutionary trajectories underlie genetic intratumoral variation in childhood cancer
Jenny Karlsson, Anders Valind, Linda Holmquist Mengelbier, Bredin, S., Louise Cornmark, Jansson, C., Wali, A., Johan Staaf, Viklund, B., Ingrid Øra, Anna Börjesson, Backman, T., Noémie Braekeveldt, Sandstedt, B., Pal, N., Isaksson, A., Lackner, B. G., Tord Jonson, Daniel Bexell & David Gisselsson, 2018
Nature Genetics. 50, 7, p. 944-950
The Iroquois homeobox proteins IRX3 and IRX5 have distinct roles in Wilms tumour development and human nephrogenesis
Linda Holmquist Mengelbier, Lindell-Munther, S., Hiroaki Yasui, Jansson, C., Esfandyari, J., Jenny Karlsson, Lau, K., Hui, C. C., Daniel Bexell, Hopyan, S. & David Gisselsson, 2019
Journal of Pathology. 247, 1
Cancer - An Insurgency of Clones
David Gisselsson & Egnell, R., 2017
Trends in Cancer. 3, 2, p. 73-75
Mosaicism in health and disease — clones picking up speed
Forsberg, L. A., David Gisselsson & Dumanski, J. P., 2017
Nature Reviews Genetics. 18, p. 128-142
Our core values can be summarised as follows:
Situation Cancer is one of the leading causes of death for children in developed countries. One main cause of cancer death is the emergence of treatment resistance through clonal evolution of cancer cells.
Mission To find new strategies to prevent and manage relapse in children with cancer. To do this, we must understand the mechanisms that make cancers adapt and become resilient to therapy.
Execution Analyses to identify evolutionary first principles that make cancer cells grow, spread, and survive microenvironmental challenges. Hypotheses will be derived from extensive patient data to be tested mechanistically in model systems.
Support Research grants are competed for in order to afford frontline genomic methods and expert data handling. Individual efforts are supported by comradeship and constructive criticism. We select collaborators based on expertise and mutual benefit.
Communication We communicate with candour, courage and consideration. We never hesitate to ask for help from our peers. Admitting ignorance and imperfection is the first step to learn.
David Gisselsson Nord
Professor of Molecular Pathology
Senior Consultant Pathologist
Division of Clinical Genetics
Department of Laboratory Medicine
Division of Oncology-Pathology
Department of Clinical Sciences
Clinical Genetics and Pathology
Phone +46 46 733 91 40 36
David [dot] Gisselsson_Nord [at] med [dot] lu [dot] se
Research group members
linda [dot] holmquist_mengelbier [at] med [dot] lu [dot] se (Linda Holmquist Mengelbier), PhD
jenny [dot] karlsson [at] med [dot] lu [dot] se (Jenny Karlsson), PhD
catharina [dot] hagerling [at] med [dot] lu [dot] se (Catharina Hagerling), MD, PhD
anders [dot] valind [at] med [dot] lu [dot] se (Anders Valind), MD, PhD
Patrik Romerius, MD, PhD
hiroaki [dot] yasui [at] med [dot] lu [dot] se (Hiroaki Yasui), MD
Bahar Rastegar, MD
caroline [dot] jansson [at] med [dot] lu [dot] se (Caroline Jansson), M.Sc.
Geffroy Durand, M.Sc.
Natalie Andersson, B.Sc.